PTC Therapeutics, Inc. (PTCT) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Momentum 1.5/10 is below the 5.0 floor at $65.43 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: Translarna; Earnings expected to decline ~72% (cyclical peak).
PTC Therapeutics is a global rare disease biopharma commercializing Sephience (PKU), Emflaza and Translarna (DMD), and Kebilidi/Upstaza (AADC deficiency), with royalty and milestone revenue from Evrysdi (SMA, partnered with Roche). Translarna's EEA marketing authorization was... Read more
Sell if holding. Momentum 1.5/10 is below the 5.0 floor at $65.43 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: Translarna; Earnings expected to decline ~72% (cyclical peak). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.7/10, moderate confidence.
Passes 4/6 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum and earnings proximity 7d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductTranslarna10-K Item 1A: 'we would lose all, or a significant portion of, our ability to generate revenue from sales of Translarna in the EEA'
Material Events(8-K, last 90d)
- 2026-03-25Item 5.02LOWJessica Chutter appointed to Board as Class I director effective March 24, 2026, filling a vacancy. Former Morgan Stanley healthcare investment banking MD with 40+ years experience. No reason for vacancy cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Revenue shrinking — -22.7% YoY. Growth thesis broken unless recovery story develops.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 1.5/10 is below the 5.0 floor at $65.43 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: Translarna; Earnings expected to decline ~72% (cyclical peak). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $61.75. Score 4.7/10, moderate confidence.
Take-profit target: $79.26 (+21.4% upside). Prior stop was $61.75. Stop-loss: $61.75.
Concentration risk — Product: Translarna; Earnings expected to decline ~72% (cyclical peak); Earnings in 7 days (event risk).
PTC Therapeutics, Inc. trades at a P/E of 7.5 (forward 26.6). TrendMatrix value score: 7.1/10. Verdict: Sell.
21 analysts cover PTCT with a consensus score of 3.8/5. Average price target: $88.
What does PTC Therapeutics, Inc. do?PTC Therapeutics is a global rare disease biopharma commercializing Sephience (PKU), Emflaza and Translarna (DMD), and...
PTC Therapeutics is a global rare disease biopharma commercializing Sephience (PKU), Emflaza and Translarna (DMD), and Kebilidi/Upstaza (AADC deficiency), with royalty and milestone revenue from Evrysdi (SMA, partnered with Roche). Translarna's EEA marketing authorization was not renewed by the European Commission in March 2025, materially threatening EEA revenue.